Skip to main content

Home/ Health affairs/ Group items matching "Pharmacy-Sale-Process-UK" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

N.B. Pharmacy sold for first time in 40 years - 0 views

  •  
    Kent based N.B. Pharmacy has been sold to first-time buyers, Venkat and Preeti Adama, from Essex for an undisclosed price. N.B. Pharmacy is a standard hours community pharmacy that dispenses an average of 6,393 items per month. The business has been owned by Nirmal Bajaria for 39 years and was recently brought to market to allow him to pursue a well-earned retirement. Following a confidential sales process with Christie & Co, it has been purchased by first-time buyers, Venkat and Preeti Adama, from Essex. Nirmal Bajaria, former owner of N.B. Pharmacy, comments, "Having run the pharmacy for around 39 years, it was a difficult decision to put the business up for sale. I was very pleased with the high number of viewers and feel delighted that a young family bought my pharmacy."
pharmacybiz

Balmedie Pharmacy UK sold to JMF Healthcare - 0 views

  •  
    Balmedie Pharmacy based in Aberdeenshire, Scotland has been purchased by local expanding multiple operator JMF Healthcare. Balmedie Pharmacy is a well-performing community pharmacy that dispenses an average of 5,255 items per month. It lies completely unopposed in the large Aberdeenshire village of Balmedie, which is circa eight miles north of Aberdeen City Centre. The pharmacy has been owned by Brian Arris since 2004 and was recently brought to market to allow him to pursue other pharmacy business opportunities. Following a confidential sales process with Christie & Co, JMF Healthcare to benefit from new housing developments in this area of Aberdeenshire such as 300 new homes planned in Balmedie, approved plans for up to 500 new homes in Trump Menie Estate, and 284 new homes planned in Blackdog Village. Brian Arris, previous owner of Balmedie Pharmacy, comments, "I'm sad to see the business go as the excellent staff have helped grow the pharmacy from scratch since 2004 and we've all put our hearts and souls into providing good pharmaceutical care for the village and surrounding area. I'm confident everyone is left in safe hands with John at the helm now."
pharmacybiz

Salrook Healthcare sold to Midlands operator - 0 views

  •  
    Salrook Healthcare, a family-run pharmacies in Chester has sold its two well-established community pharmacies named Westminster Park Pharmacy on Castle Croft Road and Owen's Chemist on Chester Street. Together, they dispense circa 13,000 items per month. The business has been owned by the Persaud family since 2014 and was recently brought to the market as a retirement sale. Following a confidential process with Christie & Co, it has been purchased by Aqib Sheikh, an existing operator with a pharmacy in Walsall, West Midlands. Aqib plans to enhance the business's service offering and grow his portfolio in the region. Chloe Yadav (nee Persaud), previous owner of Salrook Healthcare Limited, comments, "As a family, we are delighted to have completed the sale of the business to Aqib. Whilst we will miss our team who have become like family, it is good to know that the two sites have been acquired by a forward- thinking Pharmacist who will enhance the offering to the benefit of the patients and the community which they serve. My family and I wish Aqib and the whole team the very best of luck with the future." Aqib Sheikh, new owner of Salrook Healthcare Limited, comments, "I am delighted to have inherited such a well-run and profitable pair of pharmacy businesses in the charming city of Chester. I'd like to wish John Persaud the very best with his retirement and look forward to building on the work of the Persaud family."
pharmacybiz

Pharmacy2U & LloydsDirect Merger: A New Era Begins - 0 views

  •  
    Pharmacy2U has recently acquired LloydsDirect in a confidential deal, bringing together two of the UK's foremost online pharmacies. Over time, both entities will integrate their operations under the Pharmacy2U brand, the companies said in a joint statement. The two businesses complement each other effectively, and their teams will now work closely together to uphold the patient-centric approach and service quality for which both are known individually, the statement added. However, there is currently limited clarity regarding the sale process and its impact on Lloyds staff. According to NHS Business Services Authority data from PharmData, Pharmacy2U dispensed 1,528,436 items in June 2023, while LloydsDirect, previously owned by LloydsPharmacy, dispensed 1,142,891 items. This positions them as the top two online prescription pharmacies for items dispensed, with Well.co.uk in third place at 128,691 items.
pharmacybiz

Independent Pharmacies on the Rise in England: Trends & Opportunities - 0 views

  •  
    The pharmacy market in England has seen a significant transformation in recent years, driven by a trend of large-scale disposals by corporate operators. Jonathan Board, Director - Pharmacy, Christie & Co, has told Pharmacy Business that several corporate operators are looking to sell off their marginal or non-performing assets while independent operators are eager to acquire and enhance businesses further. Due to their scale, corporate operators are compelled to adopt a 'one size fits all' approach. However, Jonathan believes this puts them at a disadvantage compared to many independent operators who are better positioned to meet local patient and community needs, delivering a more personalised approach to patient engagement, and a variety of other services "As such, where corporate disposals have taken place, there has been a steady stream of independent operators eager to take over and develop the businesses further," he said.
pharmacybiz

Walgreens abandons £5bn sale of Boots UK - 0 views

  •  
    Walgreens Boots Alliance on Tuesday (June 28) scrapped the plan to sell its UK high street pharmacy chain saying no third party was able to make an adequate offer due to the turmoil in global financial markets. Walgreens' move to call off the sale comes as private equity bidders Apollo Global and TDR faced headwinds in raising financing for the deal, as banks were wary of underwriting large chunks of the financing due to tough market conditions. Boots was initially valued at as much as £8bn with the auction process being led by Goldman Sachs. Global economic uncertainty and rising inflation have triggered a spike in interest rates as central banks have rushed to take action in the most widespread tightening of monetary policy for more than two decades, making deal financing costlier and harder to access. Walgreens had put its Boots UK business up for sale after announcing a strategic review in January as the second-largest US pharmacy chain renewed its focus on domestic healthcare. The company said the decision to retain Boots and No7 Beauty Company was also underpinned by their ongoing strong performance.
pharmacybiz

Trade union Usdaw seeks assurances for members after Boots owner reportedly considers sale of pharmacy chain - 0 views

  •  
    Usdaw, one of the major trade unions in the UK, has sought assurances for its members working in Boots, following reports that the parent company of the iconic health and beauty retailer and pharmacy chain is considering putting the business on sale next year. Walgreen Boots Alliance (WBA), the US health group that owns a stake in Boots UK since 2012, is reportedly lining up Goldman Sachs to explore the sale of business with potential valuation of £10 billion. Currently, the process is thought to be solely exploratory and may not necessarily convert into the sale of the 172-year-old firm. Usdaw national officer, Daniel Adams, said: "We note that the company declined to comment on speculation, but acknowledged that the group's strategic direction 'includes a more pointed focus on North America and on healthcare'.
pharmacybiz

Ian Adamson : Maxwellia appoints s Strategic Advisor - 0 views

  •  
    Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist. Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl. Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.
pharmacybiz

Perrigo restructures management level:Strengthen local brands - 0 views

  •  
    Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.
pharmacybiz

Avacta Halts Sale Of Covid-19 Rapid Antigen LFT - 0 views

  •  
    Britain's biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies in the device and increase its ability to diagnose the Omicron variant. The company stated that AffiDX is capable of detecting Omicron when the virus is present in high numbers in samples, but the sensitivity of the test reduces at lower viral loads. The performance of all rapid antigen tests came under scanner in wake of a large number of mutations in the Omicron variant. AffiDX contains both a proprietary Affimer reagent and a commercially available antibody. The Affimer reagent detects the Omicron variant with the same sensitivity as the Delta variant, and performance of the antibody is paired with the Affimer reagent in the test. This has been affected by the additional Omicron mutations, the firm said. Alastair Smith, chief executive of Avacta Group, said: "Our determination to only provide high quality, high performance diagnostic tests has led us to the correct decision to pause all marketing of the AffiDX® lateral flow antigen test. We have, of course, been unable to market the product in the UK since October 2021, as the product continues to await approval under the new CTDA regulatory process.
pharmacybiz

Rogue Chemist Jailed: Inside the Prescription Drug Scandal - 0 views

  •  
    A drug dealer who was operating as an "unlicensed chemist" and selling prescription drugs online has been jailed for six years, according to Essex Police. The convict, identified as 49-year-old Christopher Depp, aka David Jones, was supplying a range of drugs from his home to "vulnerable people" using the postal service, local police revealed on Friday (February 16). Police conducted a search operation at his address in Wood Street, Chelmsford, in July last year and found more than 50,000 pills and tablets of varying types, stashed in toolboxes and spaces around the property. To process the large-scale sale and shipping of controlled drugs across the UK, Depp had set up a room in his property as an office space. He promoted the sale of medications through various social media platforms and messaging applications, and accepted payment from his large customer base using "fraudulently obtained" bank accounts.
1 - 11 of 11
Showing 20 items per page